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A B S T R A C T   
We report here the potential role of a 4-strain probiotic suspension for use with patients with Parkinson's disease 
(PD). Stool samples from a group of three patients with diagnosed PD were used to create microbiotas in an in- 
vitro gut model. The effects of dosing with an oral probiotic suspension (Symprove) on bacterial composition and 
metabolic activity in the microbiotas was evaluated over 48 h and compared with healthy controls. Additionally, 
the effect of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and 
wound healing were evaluated in cell culture models. In general, the relative proportions of the main bacterial 
phyla in the microbiotas of PD patients differed from those of healthy subjects, with levels of Firmicutes raised 
and levels of Bacteroidetes reduced. Dosing with probiotic resulted in a change in bacterial composition in the 
microbiotas over a 48 h period. Several other indicators of gut health changed upon dosing with the probiotic; 
production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines 
(IL-6, IL-10) increased and levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased. 
Tight junction integrity was seen to improve with probiotic dosing and wound healing was seen to occur faster 
than a control. The data suggest that if development and/or progression of PD is influenced by gut microbiota 
dysbiosis then supplementation of the diet with a properly formulated probiotic may be a useful adjunct to 
standard treatment in clinic.   
1. Introduction 
Parkinson's disease (PD) affects a significant proportion of the pop-
ulation over 65 years of age (ca. 3.7%,) and is the second most prevalent 
neurological disorder after Alzheimer's (Postuma and Berg, 2016). The 
condition is set to double in number by 2030 with a huge projected 
societal and medical burden (Dorsey et al., 2018). It is a progressive and 
chronic neurodegenerative disorder that primarily affects motor func-
tion but also includes a range of non-motor deficits. There is no cure and 
a definitive cause is not yet known. Disease progression affects multiple 
brain systems including but not limited to dopaminergic, noradrenergic, 
serotoninergic and cholinergic systems (Berg et al., 2014). Motor system 
impairments lead to a range of debilitating symptoms, including muscle 
stiffness, tremors, bradykinesia, impaired gait and postural instability. 
Non-motor symptoms include loss of smell and problems with gastro-
intestinal (GI), cardiovascular and urogenital systems (Chaudhuri et al., 
2006). 
The human gut hosts tens of trillions of microorganisms including 
more than 1000 species of bacteria, can be considered a separate enteric 
organ (Falony et al., 2016; Hill-Burns et al., 2017; Zhernakova et al., 
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2016) and is known to be affected by diet and lifestyle (Kau et al., 2011). 
James Parkinson identified gut problems as a diagnostic symptom of PD 
in his original classification of the shaking palsy (Hurwitz, 2014). Typi-
cally, patients suffer dry mouth and/or gastroparesis prior to the onset of 
motor symptoms (Cersosimo et al., 2013; Chiang and Lin, 2019; Fasano 
et al., 2015) and intractable constipation (Kaye et al., 2006) often ac-
companies or precedes (by many decades in some cases) motor 
dysfunction of PD (Elfil et al., 2020). Although there is no established 
microbial signature for constipation, microbiome changes are associated 
with gut dysbiosis (Carding et al., 2015) and are known to affect the 
absorption and metabolism of drugs (Hatton et al., 2019). This dysbiosis 
is thought to lead to a range of metabolic abnormalities including 
diminished production of neuroprotective factors, increased inflamma-
tion and neurotoxicity and adverse effects on the immune response to 
neuronal proteins (Elfil et al., 2020). PD is often characterised by a leaky 
gut denoting increased intestinal permeability, immune dysfunction 
(Bedarf et al., 2017; Dutta et al., 2019) and alpha synuclein (⍺Syn) 
accumulation (Perez-Pardoa et al., 2017). The latter are aggregates of 
insoluble fibrils found in several neuropathological conditions including 
PD. Because PD patients often have a degree of gut inflammation, faecal 
calprotectin is frequently raised (Weis et al., 2019) and has been sug-
gested as an early biomarker for PD risk (Mulak et al., 2019). The GI 
abnormalities (particularly permeability issues and the finding of in-
testinal inflammation) found in PD are common to many other diseases, 
but their importance is that these changes may reflect pathophysiolog-
ical processes that aggravate certain symptoms of PD (Tucker et al., 
2020a, 2020b). 
The gut-brain axis has long been established as a pathway for 
reciprocal communication between the enteric system and the central 
nervous system and there is growing interest in its role in the patho-
genesis of PD (Santos et al., 2019). One hypothesis is that, in susceptible 
individuals, ingested pathogens can trigger misfolding and aggregation 
of ⍺Syn deposits in the enteric nervous system which can then spread 
from the gut to the brain via the gut-brain axis (Braak et al., 2006; 
Houser and Tansey, 2017). In support of this theory, deposits of ⍺Syn 
were more frequently found in the gastrointestinal tract of PD patients 
compared with healthy controls, even in the prodromal phase of the 
condition (Bu et al., 2019), and several preclinical studies have sup-
ported the role of the vagus nerve in the bidirectional transmission of the 
synucleinopathy from the brain to the gut and vice versa (Breen et al., 
2019). 
Numerous studies (Bedarf et al., 2017; Bullich et al., 2019; Lin et al., 
2019; Qian et al., 2018; Sampson, 2020; Unger et al., 2016) have cat-
egorised the bacterial composition of the gut microbiotas in PD patients 
compared with healthy subjects. Although these studies have not iden-
tified a particular microbiota composition that always accompanies PD, 
overall there is evidence that proinflammatory dysbiosis is usually 
present (Keshavarzian et al., 2015). In experimental animal work, 
Sampson et al. (2016) highlighted that signals from the gut microbiota 
are required for the development of neuroinflammation, gastrointestinal 
dysfunction and ⍺Syn-dependent motor deficits in mice overexpressing 
⍺Syn. Choi et al. (2018) suggested that oral administration of Proteus 
mirabilis, whose abundance was found to be increased in PD mouse 
models, can trigger ⍺Syn aggregation both in the brain and in the colon 
and induce motor dysfunction, neurodegeneration as well as inflam-
mation in the substantia nigra and striatum of mice models of PD. In 
addition, mouse-to-mouse transplants of healthy microbiomes protected 
mice from dopaminergic neuronal death, even following MPTP (a 
neurotoxin that induces Parkinsonian symptoms) (Sun et al., 2018). 
When MPTP was combined with exposure to P. mirabilis there was 
increased loss of dopaminergic neurons and worse motor impairment 
compared with MPTP treatment alone (Choi et al., 2018). Taken 
together, these results show that the gut microbiota could modulate the 
phenotypes associated with standard models of PD pathology. 
In previous studies on probiotic use in human health and disease, we 
have shown that dosing with a 4-strain live probiotic suspension 
(Symprove™) had the potential to change the balance of species in the 
gut microbiotas of healthy human donors (Moens et al., 2019) and pa-
tients with ulcerative colitis (Ghyselinck et al., 2020) in an in-vitro 
model. Symprove showed excellent tolerance to gastric acid during in- 
vitro testing (Fredua-Agyeman and Gaisford, 2015), partly explaining its 
effectiveness in ameliorating the clinical symptom severity scores of a 
number of gut conditions in clinical studies. For instance, Symprove 
reduced clinical symptom severity scores in IBS (Sisson et al., 2014) and 
reduced abdominal pain scores and significantly reduced constipation, 
diarrhoea and mucorrhoea in diverticular disease (Kvasnovsky et al., 
2017). Symprove has also shown anti-pathogenic activity against 
various common gut pathogens, including Clostridium difficile (Fredua- 
Agyeman et al., 2017), Escherichia coli, methicillin-resistant Staphylo-
coccus aureus (MRSA) and Shigella sonnei (Dodoo et al., 2019). 
Unsurprisingly, probiotic formulations have been mooted as a di-
etary supplement that might improve intestinal health and disease 
(Sanders et al., 2019) and alleviate PD symptoms (Gazerani, 2019), 
although reports of positive clinical effects with probiotic supplemen-
tation on PD progression are lacking. Confidence in the use of probiotic 
supplements in the management of PD will increase if there is evidence 
that probiotic bacteria can integrate and assimilate into an existing gut 
microbiota, improving overall gut health. Thus, the primary research 
objectives of this work were (i) to determine whether addition of the 
probiotic bacteria in Symprove could influence bacterial composition in 
the microbiotas of patients with PD and (ii) to determine whether other 
indicators of gut health in PD patients could be improved with probiotic 
supplementation. The results allowed a mechanism by which probiotic 
bacteria exert a positive effect to be established. The experimental dif-
ficulties of making such measurements in-vivo meant we employed an in- 
vitro dynamic, multi-compartment gastrointestinal model (the simulator 
of the human intestinal microbial ecosystem, equipped with a mucosal 
compartment, M-SHIME®). 
2. Materials and methods 
2.1. Symprove 
Symprove, an aqueous suspension containing Lactobacillus acidophi-
lus NCIMB 30175, Lactobacillus plantarum NCIMB 30173, Lactobacillus 
rhamnosus NCIMB 30174 and Enterococcus faecium NCIMB 30176, was 
obtained from Symprove Ltd. and used as received. 
2.2. Donors 
Faecal samples were obtained from six donors; three healthy control 
subjects and three diagnosed with PD. Each of the PD donors was on an 
established drug treatment regimen, details of which are shown in 
Table 1, and none had been on antibiotics in the three months prior to 
donation. Samples were collected according to the ethical approval of 
the University Hospital Ghent (reference number: B670201836585). 
2.3. M-SHIME® testing 
The M-SHIME® system was configured for short-term batch experi-
ments (full details of the experimental arrangement of the M-SHIME® 
system are described elsewhere; Van den Abbeele et al., 2010; Van den 
Table 1 
Details of the drug treatment regimens of the three PD donors (all doses per day).  
Donor 
number 
Drug treatment regimen 
1 Artane 
2 Azilect 1 mg, Requip 8 mg, Cymbalta, Silodyx, Melatonine 5 mg, 
Rilatine 2 × 10 mg 
3 Azilect 1 mg, Requip 8 mg, Efexor 75 mg  
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Abbeele et al., 2012; Van den Abbeele et al., 2013). Briefly, this involved 
fermentation of faecal samples in single vessels in the presence or 
absence of the probiotic bacteria in Symprove. A sugar-depleted basal 
nutritional medium (56 mL) buffered at pH 6.5, containing the nutrients 
present in the colon (5.9 g/L K2HPO4, 18.3 g/L KH2PO4, 2.3 g/L 
NaHCO3, 2.3 g/L yeast extract, 2.3 g/L peptone, 0.6 g/L cysteine and 
2.3 mL/L Tween 80) was co-administered with Symprove (7 mL) at the 
start of fermentation. A corresponding series of blank experiments were 
conducted by adding the basal nutritional medium to distilled water (7 
mL, instead of Symprove). Subtraction of the blank data from the 
Symprove data allowed the effects of the probiotic formulation to be 
determined. A 7.5% (w/v) faecal suspension was prepared from each PD 
donor in anaerobic phosphate buffer (K2HPO4 8.8 g/L; KH2PO4 6.8 g/L; 
sodium thioglycolate 0.1 g/L; sodium dithionite 0.015 g/L) and was 
inoculated (7 mL) into the reactors, bringing the total volume to 70 mL. 
Finally, five mucin-covered microcosms were added to all colonic ves-
sels, enabling maintenance of not only a luminal microbiota but also a 
specific mucosal microbiota in the colonic vessels. Each incubation was 
performed in triplicate, resulting in 36 independent incubations. The 
headspace of the vessels was flushed with nitrogen to ensure anaerobic 
conditions and incubations were performed for 48 h at 37 ◦C under 
continuous shaking. 
2.4. Measurement of microbial metabolites and protein metabolism 
SCFA levels, including acetate, propionate, butyrate and the 
branched-chain fatty acids (bCFA) isobutyrate, isovalerate and iso-
caproate, were monitored with gas chromatography (GC) coupled with 
flame ionization detection (FID). After addition of 2-methyl hexanoic 
acid as an internal standard, a sample (2.0 mL) was extracted with 
diethyl ether. The extracts were analyzed using a GC-2014 gas chro-
matograph (Shimadzu, ‘s-Hertogenbosch, the Netherlands), equipped 
with a GC SGE capillary column, 30 m × 0.32 mm ID-BP21x 0.25 μm 
(Achrom, Machelen, Belgium), a flame ionization detector and a split 
injector. The injection volume was 1 μL and the column temperature 
profile was set from 110 to 160 ◦C, rising at 6 ◦C min− 1. The carrier gas 
was nitrogen and the temperatures of the injector and detector were 
both 200 ◦C. 
Lactate quantification was performed using a commercially available 
enzymatic assay kit (R-Biopharm,Darmstadt, Germany) according to the 
manufacturer's instructions. Ammonium analysis was performed as 
previously described (Van de Wiele et al., 2004). Briefly, the ammonium 
in the liquid samples was quantified by initially performing a steam 
distillation. Subsequently, the ammonium in the distillate was deter-
mined titrimetrically with HCl. 
2.5. Microbial community analysis 
Illumina sequencing was performed at the beginning and end (48 h) 
of fermentation. Because the Illumina sequencing method is polymerase- 
chain reaction (PCR) based, microbial gene sequences are amplified 
until saturation is reached, meaning results at the phylogenetic level 
(phylum, family, genus and operational taxonomic unit, OTU) are 
expressed as proportional values. Two primers, 341F (5’-CCT ACG GGN 
GGC WGC AG − 3′) and 785Rmod (5’-GAC TAC HVG GGT ATC TAA 
KCC-3′) (Klindworth et al., 2013), were used that spanned the hyper-
variable regions V3 and V4 of the 16 s rDNA. PCR products were run 
along DNA extracts on a 2% agarose gel for 30 min at 100 V. A sample 
(10 μL) of the original genomic DNA extract was sent for library prep-
aration and sequencing on an Illumina Miseq platform with v3 chem-
istry with the primers mentioned above (LGC genomics GmbH, 
Germany). 
2.6. Caco-2/THP1-blue™ co-culture model 
Caco-2 cells (HTB-37, American Type Culture Collection) were 
seeded in semi-permeable inserts (24-well, 0.4 μm pore size) at a density 
of 1 × 105 cells/insert. The cells were cultured for 14 days, with three 
changes of medium per week, until a functional monolayer with a 
transepithelial electrical resistance (TEER) of more than 300 Ω cm2 was 
obtained. TEER was measured with a Millicell ERS-2 epithelial volt-ohm 
meter (Millipore). Cells were maintained in Dulbecco's Modified Eagle 
Medium (DMEM) containing glucose (25 mM) and glutamine (4 mM), 
supplemented with HEPES (10 mM) and heat-inactivated foetal bovine 
serum (HI-FBS, 20% v/v). 
THP1-Blue™ cells (InvivoGen) were seeded in 24-well plates at a 
density of 5 × 105 cells/well and treated with phorbol 12-myristate 13- 
acetate (PMA) for 48 h. Roswell Park Memorial Institute (RPMI) 1640 
medium containing glucose (11 mM) and glutamine (2 mM), supple-
mented with HEPES (10 mM), sodium pyruvate (1 mM) and HI-FBS 
(10% v/v), was used to maintain the cells. 
To set up the co-culture, Caco-2 bearing inserts were placed on top of 
the PMA-differentiated THP1-blue™ cells. Sterile-filtered (0.22 μm) 
colonic SHIME media (diluted 1:5 v/v in Caco-2 complete medium) was 
placed in the apical (Caco-2) compartment. The basolateral (THP1- 
blue™) compartment was filled with Caco-2 complete medium. Sodium 
butyrate (12 mM, Sigma-Aldrich) was added to the apical compartment 
as a positive control. Cells were treated for 24 h, after which the TEER 
was measured. The basolateral compartment was then emptied, and 
cells were stimulated on the basolateral side with either (i) Caco-2 
complete medium containing ultrapure lipopolysaccharide (LPS, E. coli 
K12, InvivoGen), (ii) Caco-2 complete medium with LPS and hydro-
cortisone (HC, Sigma-Aldrich) or (iii) Caco-2 complete medium without 
LPS. After LPS stimulation (6 h) the basolateral supernatants were 
collected for cytokine measurement (human TNF-α, IL-6, IL-8, IL-10, and 
CXCL10) by Luminex® multiplex (Affymetrix-eBioscience). The THP1- 
Blue™ cells contain a stably transfected reporter construct allowing the 
expression of a secreted alkaline phosphatase (SEAP) under the control 
of an NF-κB inducible promoter. Hence, upon LPS stimulation, NF-κB is 
activated, leading to the secretion of SEAP in the basolateral medium. 
Then, SEAP activity was measured in the basolateral medium using the 
QUANTI-Blue™ reagent (Invivogen). All measurements were performed 
in triplicate and cells were incubated at 37 ◦C in a humidified atmo-
sphere of air/CO2 (95,5 v/v). 
2.7. Scratch wound healing assay 
T84 cells (Sigma-Aldrich) were seeded in 24-well plates and cultured 
for 7 days, with three changes of medium per week, until a complete, 
confluent, cell monolayer was formed. Cells were maintained in a basal 
medium (DMEM/F-12) containing L-glutamine and HEPES supple-
mented with antibiotic/antimycotic (Gibco, Life Technologies) and 5% 
HI-FBS. Cells were incubated at 37 ◦C in a humidified atmosphere of air/ 
CO2 (95:5 v/v). 
After 7 days a scratch was created in the monolayer, followed by 
treatment with 1/10 diluted colonic suspensions in serum-free T84 
culture medium. Images were captured with a Cytation 5 Cell Imaging 
Multi-mode Reader at the initial time point (0 h) and after incubation 
(24 h). Images were compared in order to quantify the migration rate of 
the cells while the wound area was measured using ImageJ®. Serum- 
free culture medium and 5 mM NaB (Sigma-Aldrich) were used as 
negative and positive controls respectively. All measurements were 
conducted in triplicate. 
2.8. Statistical tests for the cell assays 
To evaluate differences in TEER and immune markers, colonic batch 
treatment samples were compared with their respective control samples 
using a two-way ANOVA with Sidak's multiple comparisons test. For the 
pure product, statistical significance for the TEER was calculated by 
using one-way ANOVA with Dunnett's multiple comparisons test and the 
different concentrations of Symprove were compared with CM. For the 
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wound healing assay, statistical significance between CM and sodium 
butyrate was calculated with an unpaired, two-tailed t-test with Welch's 
correction. To evaluate differences in wound area, colonic batch treat-
ment samples were compared with their respective control samples 
using a two-way ANOVA with Sidak's multiple comparisons test. For 
pure product, statistical significance was calculated by using one-way 
ANOVA with Dunnett's multiple comparisons test against CM. Statisti-
cally significant differences are represented by (*). (*), (**), (***) and 
(****) represent p < 0.05, p < 0.01, p < 0.001 and p < 0.0001, 
respectively. 
All samples were taken as biological replicates in the cell assays (n =
3/donor) and statistics were performed on the average of the replicates. 
3. Results and discussion 
Tables 2 and 3 show the predominant phyla in the microbiotas of the 
healthy subjects and the PD patients before dosing with Symprove. The 
predominant phyla were Firmicutes, Bacteroidetes and Actinobacteria, 
although the PD patients showed lower levels of Firmicutes (70.3 ±
3.5%) and higher levels of Bacteroidetes (19.0 ± 15.1%) than healthy 
subjects (81.5 ± 10.8% and 10.5 ± 4.4% respectively). Tables 4 and 5 
show the predominant phyla in the microbiotas of the healthy subjects 
and the PD patients after dosing with Symprove (familial detail of OTUs 
within phyla are given in Tables S1-S4). Tables 6 and 7 show the 
composition of the gut microbiota at bacterial family level. 
Although the data cover only a 48 h period, some significant changes 
in bacterial composition are apparent. Considering the healthy subjects 
first, levels of Firmicutes, Actinobacteria and Bacteroidetes were raised. 
Two of the bacteria in Symprove (L. plantarum and L. rhamnosus) were 
significantly enriched in the luminal compartments of all three donors 
and in the mucosal compartments of two of the donors, contributing to 
the raised level of Firmicutes. Other contributors to the increase in Fir-
micutes included Lachnospiraceae, Ruminococcaceae, Selenomonadaceae, 
Streptococcaceae and Veillonellaceae. The proportion of Actinobacteria 
increased, principally by enrichment of Bifidobacteriaceae in the lumen 
of all donors. Coriobacteriaceae were enriched in the luminal compart-
ments of two donors while Eggerthellaceae were enriched in the other 
donor. The proportion of Bacteroidetes was also raised, enriched by 
B. uniformis and Rikenellaceae in the lumen of donor 2. Tannerellaceae 
(principally Parabacteroides distasonis) was enriched in the luminal 
compartments of donors 2 and 3 and in the mucus of donor 1. The 
proportion of Proteobacteria reduced, principally through a lower 
abundance of Escherichia coli across the three donors (although it is 
noted that there may not have been an absolute reduction in Proteo-
bacteria numbers, because the reduction in proportion could be caused 
by outgrowth in the other phyla). 
In the PD patients the proportions of Actinobacteria and Firmicutes 
were raised. Enrichment of Firmicutes in the lumen of all donors and the 
mucus layer of donors 1 and 2 reflected partly the integration and 
proliferation of L. plantarum and L. rhamnosus from Symprove, but had 
contributions from other families, in particular Eubacteriaceae, Lachno-
spiracaea, Streptococcaceae and Veillonellaceae in the lumen and Erysi-
pelotrichaceae, Lachnospiraceae and Veillonellaceae in the mucus. 
Bifidobacteriaceae stimulation (in particular Bifidobacterium longum) 
accounted for the elevation in Actinobacteria levels. 
Many studies have shown the gut microbial profiles in those with PD 
differ from healthy subjects (Bedarf et al., 2017; Lin et al., 2019; Qian 
et al., 2018; Sampson, 2020; Unger et al., 2016). Species that have been 
found to be enriched in PD patients include Akkermansia, Alistipes shahii, 
Table 2 
Composition (%) at the phyla level of the microbiotas of the three healthy donors 
before dosing with probiotic.  
Phyla Donor 1 Donor 2 Donor 3 
Firmicutes 86.7 69.1 88.7 
Bacteroidetes 8.9 15.4 7.1 
Actinobacteria 2.5 15.2 3.9 
Proteobacteria 1.1 0.3 0.3 
Verrucomicrobia 0.9 0.0 0.0  
Table 3 
Composition at the phyla level of the microbiotas of the three PD donors before 
dosing with probiotic.  
Phyla Donor 1 Donor 2 Donor 3 
Firmicutes 70.9 73.4 66.5 
Bacteroidetes 13.2 22.2 21.7 
Actinobacteria 14.1 3.0 6.1 
Proteobacteria 0.9 0.8 5.2 
Verrucomicrobia 0.8 0.3 0.2  
Table 4 
Composition (%) in the lumen and in the mucosal layer at the phyla level of the microbiotas of the three healthy donors after 48 h in the M-SHIME® system (B, blank; P, 
dosing with probiotic).  
Phyla Donor 1 Lumen 
Donor 2 
Donor 3 Donor 1 Mucus 
Donor 2 
Donor 3 
B P B P B P B P B P B P 
Firmicutes 12 14 14 24 14 19 39 49 51 80 32 67 
Proteobacteria 60 65 40 18 52 33 3 2 13 2 9 3 
Bacteroidetes 22 18 45 42 32 41 56 47 35 18 55 21 
Verrucomicrobia 6 2 0 0 0 0 1 1 0 0 0 0 
Actinobacteria 0 1 2 16 1 6 1 2 1 1 4 9  
Table 5 
Composition (%) in the lumen and mucus at the phyla level of the microbiotas of the three PD donors after 48 h in the M-SHIME® system (B, blank; P, dosing with 
probiotic).  
Phyla Lumen Mucus 
Donor 1 Donor 2 Donor 3 Donor 1 Donor 2 Donor 3 
B P B P B P B P B P B P 
Firmicutes 43 47 19 46 25 42 30 41 41 50 31 30 
Proteobacteria 26 26 29 25 36 34 13 13 20 11 10 21 
Bacteroidetes 20 17 25 27 38 20 40 22 33 34 56 37 
Verrucomicrobia 8 4 26 1 0 0 9 4 4 0 0 0 
Actinobacteria 1 6 0 0 0 4 8 21 1 5 2 12  





Composition (%) in the original inocula, the lumen after 48 h and the mucosal layer after 48 h at the family level of the microbiotas of the three healthy donors in the M-SHIME® system (B, blank; P, treatment with 
probiotic).  
Phylum Family Donor 1 Donor 2 Donor 3 
Inoculum Lumen Mucus Inoculum Lumen Mucus Inoculum Lumen Mucus 
B P B P B P B P B P B P 
Actinobacteria Bifidobacteriaceae 1.0 0.1 0.5 0.3 0.8 14.3 1.4 15.5 0.6 0.3 3.7 0.7 5.6 1.7 2.5 
Coriobacteriaceae 1.3 0.0 0.0 0.4 0.8 0.9 0.0 0.1 0.2 0.2 0.1 0.0 0.0 2.2 6.5 
Eggerthellaceae 0.2 0.2 0.2 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.5 0.6 0.1 0.1 
Bacteroidetes Bacteroidaceae 5.8 20.2 17.2 55.8 46.6 15.1 42.5 36.7 33.9 17.8 6.3 26.2 23.6 45.1 14.6 
Bacteroidales_unclassified 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.9 0.0 0.0 
Muribaculaceae 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Prevotellaceae 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 
Rikenellaceae 0.3 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.1 0.0 0.0 0.0 0.1 0.1 
Tannerellaceae 0.1 1.3 1.1 0.3 0.5 0.2 1.8 4.3 0.9 0.4 0.5 5.8 16.5 9.8 6.1 
Firmicutes Acidaminococcaceae 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.7 1.0 1.4 0.8 
Anaerovoracaceae 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Butyricicoccaceae 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 
Christensenellaceae 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Clostridia_UCG-014_fa 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Clostridiaceae 0.3 0.0 0.0 0.0 0.0 0.2 1.6 1.1 21.8 3.6 0.0 0.0 0.0 0.2 0.0 
Enterococcaceae 0.0 1.6 0.1 0.5 0.1 0.0 0.6 0.0 0.2 0.0 0.0 0.9 0.0 2.7 0.2 
Erysipelatoclostridiaceae 0.6 0.0 0.0 0.1 0.1 0.7 0.0 0.1 0.0 0.0 0.1 0.2 0.0 1.1 1.4 
Erysipelotrichaceae 0.1 0.0 0.0 0.3 0.2 1.6 0.0 0.0 0.1 0.1 0.4 0.0 0.0 1.7 2.8 
Lachnospiraceae 54.4 9.7 8.9 35.7 47.3 43.5 11.1 13.2 26.9 75.3 81.3 12.5 13.4 24.1 58.7 
Lactobacillaceae 0.1 0.0 3.9 0.0 0.4 0.0 0.0 7.5 0.0 0.1 0.0 0.0 4.7 0.0 0.8 
Monoglobaceae 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
Oscillospiraceae 2.0 0.4 0.3 1.3 0.2 0.3 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 
Oscillospirales_fa 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Peptococcaceae 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Peptostreptococcaceae 6.7 0.0 0.0 0.0 0.1 4.4 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.2 0.4 
Ruminococcaceae 13.8 0.1 0.1 0.9 0.2 15.5 0.0 0.0 0.7 0.2 5.7 0.0 0.0 0.5 1.3 
Selenomonadaceae 0.0 0.0 0.0 0.0 0.0 2.2 0.1 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Streptococcaceae 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.5 
Veillonellaceae 5.1 0.4 0.3 0.2 0.2 0.1 0.3 0.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 
Proteobacteria Desulfovibrionaceae 0.6 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 
Enterobacterales_unclassified 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 
Enterobacteriaceae 0.5 60.0 65.0 3.4 1.5 0.0 39.5 18.1 13.4 1.6 0.0 52.1 33.2 8.7 2.9 
Sutterellaceae 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Verrucomicrobia Akkermansiaceae 0.9 5.5 1.8 0.8 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Unclassified Bacteria_unclassified 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
J. G





Composition (%) in the original inocula, the lumen after 48 h and the mucosal layer after 48 h at the family level of the microbiotas of the three PD donors in the M-SHIME® system (B, blank; P, dosing with probiotic).  
Phylum Family Donor 1 Donor 2 Donor 3 
Inoculum Lumen Mucus Inoculum Lumen Mucus Inoculum Lumen Mucus 
B P B P B P B P B P B P 
Actinobacteria Bifidobacteriaceae 5.8 0.9 5.7 8.2 20.8 0.3 0.1 0.3 1.4 4.3 1.5 0.1 3.5 2.1 12.3 
Coriobacteriaceae 6.6 0.3 0.4 0.1 0.3 2.2 0.0 0.0 0.0 0.6 2.7 0.0 0.0 0.0 0.0 
Coriobacteriales Incertae Sedis 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Eggerthellaceae 1.1 0.1 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 
Propionibacteriaceae 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Bacteroidetes Bacteroidaceae 1.3 15.0 13.7 27.9 14.2 6.2 20.8 22.3 24.7 25.8 9.1 34.1 17.0 55.0 35.8 
Bacteroidales_unclassified 11.3 0.1 0.1 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Bacteroidia_unclassified 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Barnesiellaceae 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
Marinifilaceae 0.0 0.0 0.0 0.0 0.0 0,1 0.1 0.1 0.2 0.0 0.7 0.3 0.1 0.0 0.0 
Muribaculaceae 0.0 0.0 0.0 0.0 0.0 14.4 0.0 0.0 0.0 0.0 8.6 0.0 0.0 0.0 0.0 
Prevotellaceae 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Rikenellaceae 0.2 0.1 0.6 0.1 0.1 0.4 0.1 0.1 0.0 0.0 1.8 0.1 0.1 0.0 0.0 
Tannerellaceae 0.2 4.1 2.7 11.4 7.2 0.4 3.7 4.8 8.0 8.3 1.4 3.3 2.9 0.8 0.9 
Veillonellaceae 0.0 0.1 20.3 0.0 0.8 1.9 0.0 12.5 0.0 7.1 0.0 0.2 3.6 0.0 0.4 
Firmicutes Acidaminococcaceae 0.4 0.6 0.5 0.3 0.2 0.2 2.4 1.2 1.6 0.9 3.0 5.3 2.4 3.6 1.5 
Christensenellaceae 3.6 0.0 0.1 0.0 0.0 3.0 0.0 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 
Clostridiaceae 1 1.0 7.8 0.9 13.8 15.1 1.0 0.5 0.1 30.0 4.2 0.3 2.2 0.3 21.5 9.3 
Clostridiales_unclassified 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.9 1.0 0.4 0.2 
Clostridiales vadinBB60 group 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Enterococcaceae 0.0 26.0 3.3 10.9 7.3 0.0 3.9 1.8 5.9 1.9 0.2 4.6 7.6 0.9 2.1 
Erysipelotrichaceae 4.0 0.1 0.9 0.2 5.7 1.4 0.0 0.0 0.0 0.4 1.6 0.0 0.1 0.0 0.3 
Eubacteriaceae 0.0 0.0 0.0 0.0 0.0 0.0 1.1 2.8 0.3 0.5 0.1 4.4 6.9 0.4 0.5 
Family_XI 0.0 0.1 0.4 0.0 0.0 0.2 0.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 
Family_XIII 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 
Lachnospiraceae 39.1 1.8 2.4 3.6 9.1 27.1 4.5 8.8 1.0 28.2 32.3 6.4 8.8 4.1 14.1 
Lactobacillaceae 0.0 0.0 7.9 0.0 0.6 0.0 0.0 7.7 0.0 0.9 0.1 0.0 10.9 0.0 0.7 
Peptostreptococcaceae 2.0 1.5 0.8 1.0 0.4 9.5 0.2 0.1 0.3 0.2 1.5 1.1 0.1 0.3 0.1 
Ruminococcaceae 20.0 0.4 0.7 0.1 0.3 28.6 0.1 0.1 0.0 0.1 23.9 0.2 0.2 0.0 0.2 
Streptococcaceae 0.4 4.6 8.5 0.3 1.2 0.0 6.5 10.8 2.3 5.1 0.0 0.0 0.0 0.0 0.1 
Fusobacteria Fusobacteriaceae 0.0 1.3 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Proteobacteria Burkholderiaceae 0.5 0.4 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 3.8 0.3 0.0 0.1 0.0 
Desulfovibrionaceae 0.3 0.1 0.0 0.0 0.0 0.4 0.1 0.2 0.0 0.0 1.1 0.1 0.1 0.0 0.0 
Enterobacteriaceae 0.0 25.8 25.2 12.5 12.7 0.0 28.9 25.3 20.3 11.0 0.2 35.1 34.2 10.3 21.2 
Synergistetes Synergistaceae 0.0 0.7 0.1 0.0 0.0 0.1 1.0 0.2 0.2 0.1 0.1 0.9 0.0 0.0 0.0 
Tenericutes Mollicutes_RF39_fa 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
Uncultured uncultured 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 
Verrucomicrobia Akkermansiaceae 0.4 7.8 3.9 8.9 3.6 0.1 25.8 0.6 3.7 0.2 0.2 0.3 0.1 0.0 0.0 
Puniceicoccaceae 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
J. G
hyselinck et al.                                                                                                                                                                                                                             
International Journal of Pharmaceutics: X 3 (2021) 100087
7
Bifidobacteriaceae, Bilophila, Butyricimonas, Christensenellaceae, Entero-
coccus, Firmicutes, Lachnospiraceae, Lactobacillaceae, Mucispirillum, 
Odoribacter, Pasteurellaceae, Prevotellaceae, Porphyromonas, Tissier-
ellaceae, Veillonella and Verrucomicrobiaceae. Species decreased in PD 
patients include Clostridium saccharolyticum, Erysipelotrichaceae (Eubac-
terium biforme), Faecalibacterium, members of the Lachnospiraceae fam-
ily, including Blautia sp. and Roseburia sp., Lactobacillaceae and 
Prevotellaceae (Prevotella copri). These findings are not easily interpreted 
because of variations in methodology, sequencing, data collection, data 
analyses and variations across individuals in severity of condition, time 
since onset, medication, gender, ethnicity and geographical location 
(which is why machine learning may be a promising approach for 
identifying changes in microbial composition and linking them to dis-
ease progression, McCoubrey et al., 2021). It is clear from this study, 
however, that even a single dose of probiotic was able to effect a change 
in microbial diversity over 48 h, meaning that if development and/or 
progression of PD is influenced by gut microbiota dysbiosis then pro-
biotic supplementation of the diet might be beneficial. 
Fig. 1 shows the production and consumption of lactate and SCFA 
with time after dosing the donor microbiotas with probiotic. Lactate 
concentrations rose substantially in the first 6 h and then fell during the 
rest of the test as it was consumed. Acetate concentrations raised after 6 
h but thereafter its utilisation in health and PD microbiomes differed; in 
healthy microbiomes there was considerable utilisation of acetate, while 
in PD microbiomes it continued to accumulate. Propionate and butyrate 
concentrations did not start to increase until 24 h. Propionate levels 
were fairly consistent in all microbiomes. Butyrate levels increased in all 
microbiomes, but the increase was greater in healthy subjects. 
The changes in SCFA concentrations result from the integration of 
the probiotic bacteria into the existing microbiota, followed by stimu-
lation of various commensal bacterial groups through cross-feeding in-
teractions (Moens et al., 2019). Fermentation of carbohydrate by the 
lactic-acid bacteria in Symprove means lactate is the first compound to 
increase in concentration; lactate does not, however, accumulate in the 
system because it is a substrate for propionate-producing species, such as 
Veillonella and Megasphaera (Reichardt et al., 2014), and butyrate- 
producing species, such as Anaerostipes caccae and E. hallii (Duncan 
et al., 2004a; Flint et al., 2015; Louis et al., 2014). Acetate results from 
saccharolytic fermentation by numerous bacterial groups including 
Bifidobacteria (De Vuyst et al., 2014), Bacteroidetes (Baxter et al., 2019: 
Macy et al., 1978) and acetogenic bacteria (Ragsdale and Pierce, 2008) 
and in human faeces it is the most abundant SCFA (accounting for more 
than 50% of the total, Louis et al., 2007). Finally, acetate is itself a 
substrate for many butyrate-producing species (such as Faecalibacterium 
prausnitzii and Roseburia spp., Duncan et al., 2004b) and is an essential 
co-substrate that must be consumed to enable butyrate synthesis from 
lactate or carbohydrate (Duncan et al., 2002). 
It is well accepted that production of lactate and short-chain fatty 
acids (SCFA) by gut bacteria as a result of carbohydrate fermentation is 
key to good health. Of the SCFAs, acetate, propionate and butyrate are 
the most important in human health (Tremaroli and Bäckhed, 2012). 
These compounds are used as energy sources for commensal gut bacteria 
(acetate and propionate), peripheral tissues (acetate and propionate) 
and colonocytes (butyrate) (Hamer et al., 2008) but they also impact 
inflammation, vasodilation, gut motility and wound healing (Bergman, 
1990). Lactate, although not an SCFA, is preferred to glucose as an 
Fig. 1. Effect of probiotic (Symprove) on the SCFA concentrations in the microbiotas of three PD donors compared with healthy control donors as a function of 
incubation time. Lactate (top left), acetate (top right), propionate (bottom left) and butyrate (bottom right). Data are shown as mean +/− standard deviation. 
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energy source by neurons. 
A recent review of the role of diet in the development of PD showed 
that general characteristics of the microbiota in patients with PD are a 
reduction in SCFA-producing bacteria and an increase in genes coding 
for lipopolysaccharides (Jackson et al., 2019). Despite evidence of 
reduced SCFA concentrations in the faeces of PD patients, Shin et al. 
(2020) found that acetate concentrations were significantly higher in the 
blood plasma of PD patients compared with controls after adjusting for 
covariates. They concluded that their findings indicated leakage of in-
testinal SCFAs because of subclinical inflammation induced by an 
altered microbiota in PD (i.e. the increased SCFA concentrations in blood 
plasma were not a marker of health in PD patients but rather a possible 
sign of altered metabolism/gut dysbiosis). Unger et al. (2016) quanti-
tatively analyzed SCFA concentrations and microbiota composition in 
faecal samples of 34 PD patients and 34 age-matched controls. They 
found a significant absolute and relative reduction in faecal SCFA 
compared with matched and young healthy controls, consistent with the 
observed altered gut microbiota composition. Notably, they found a 
reduction in Lactobacillaceae in the PD group and increased abundance 
of Enterobacteriaceae. 
Once dietary carbohydrate has been exhausted, gut microbes will 
start to metabolise protein, producing various metabolic by-products 
including ammonium, numerous branched-chain fatty acids (bCFA), 
principally isobutyrate, isovalerate and isocaproate, and several amines, 
phenols/indoles and sulphides. Fig. 2 shows the bCFA and ammonium 
concentrations recorded in the microbiotas following dosing with 
Symprove; small concentrations of bCFAs and ammonium were seen 
after 6 h in all samples but were reduced after 48 h. Since these com-
pounds are generally viewed as detrimental to human health (Scott 
et al., 2013) low levels are desirable and it is seen here that for all donors 
concentrations reduced after dosing with probiotic. In order to try and 
visualise the changes in SCFA, bCFA and ammonium levels following 
dosing with Symprove, principal component analysis plots (Fig. S1) are 
given in SI for both healthy and PD donors. 
Table 8 shows the TEER values for Caco-2/THP1 cells treated with 
colonic media with and without dosing with Symprove for 24 h. For all 
donors TEER values without probiotic (healthy subjects, 83.3 ± 1.1; PD 
patients, 57.3 ± 1.7) were lower than the complete medium controls 
(healthy subjects, 88.8 ± 0.71; PD patients, 68.0 ± 1.8) while following 
dosing with probiotic TEER values were significantly higher for all do-
nors (healthy subjects, 107.3 ± 3.3; PD patients, 76.3 ± 1.7, p < 0.001). 
Table 9 shows the TEER values measured when the apical side of the cell 
model was incubated with various concentrations of probiotic bacteria 
for 24 h; no increase in TEER was seen in these experiments. 
Loss of epithelial tight-junction integrity and an increase in inflam-
matory markers are well-recognised factors in a number of disease states 
(Artis, 2008), and PD in particular (Dutta et al., 2019). The clinical issue 
is whether loss of the gut wall barrier function in PD patients is caused 
by dysbiosis in their gut microbiota and whether improvement is caused 
by simple addition of probiotic bacteria or by the influence of probiotic 
bacteria on the gut microbiota. Tight-junction integrity was quantified 
here with an in-vitro bilayer cell model comprising epithelial-like cells 
(Caco-2 cells) and immune cells of human origin (THP1 cells). The fact 
that following dosing with probiotic TEER values were significantly 
higher for all donors is not surprising, since many studies have shown 
positive effects of Lactobacillus and/or butyrate on TEER and wound 
healing (Gudadappanavar et al., 2017; Ma et al., 2012; Peng et al., 2009; 
Wang et al., 2012). 
The question is whether these positive effects on TEER arise from 
simple addition of the probiotic bacteria or from stimulation of the 
microbiome as a whole. No increase in TEER was seen when the apical 
side of the cell model was incubated with various concentrations of 
probiotic bacteria for 24 h, indicating that the presence of the probiotic 
bacteria alone had no effect on gut barrier function. When exposed to 
Fig. 2. Effect of probiotic (Symprove) on the protein metabolite concentrations in the microbiotas of three PD donors compared with healthy control donors as a 
function of incubation time. bCFA (left) and ammonium (right). Data are shown as mean +/− standard deviation. 
Table 8 
Effect of colonic batch samples from healthy and PD donors on the trans-
epithelial electrical resistance of the Caco-2/THP1 co-cultures. TEER was 
measured 24 h after dosing with probiotic (P). Samples without added probiotic 
were used as blanks (B). Δ shows the difference between control and probiotic.   
Healthy PD 
B P Δ B P Δ 
Donor 1 86 ± 0.7 113 ± 2.4 27 ± 2.5 61 ± 1 79 ± 2 18 ± 2.2 
Donor 2 82 ± 1.4 105 ± 4.1 23 ± 4.3 54 ± 1 73 ± 1 19 ± 1.4 
Donor 3 82 ± 1.3 104 ± 2.6 22 ± 2.9 57 ± 3 77 ± 2 20 ± 3.6  
Table 9 
Effect of probiotic bacteria on the transepithelial 
electrical resistance of the Caco-2/THP1 co-cul-
tures. TEER was measured 24 h after dosing.  
Concentration TEER 
105 bacteria 64 ± 2 
106 bacteria 62 ± 1 
107 bacteria 71 ± 2  
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sodium butyrate (12 mM) for 24 h an increase in TEER was observed 
(110.3 ± 1.3, p < 0.001). The implication from these results is thus that 
it is not the simple addition of probiotic bacteria to the gut that results in 
an improvement in epithelial tight-junction integrity, but the stimula-
tory effect of the probiotic bacteria on the commensal gut bacteria, and 
the resultant increase in SCFA concentration (butyrate in particular). 
Fig. 3 shows the NF-κB activity, Fig. 4 shows the concentrations of 
anti-inflammatory cytokines IL-6 and IL-10 and Fig. 5 shows the con-
centrations of pro-inflammatory cytokines and chemokines TNFα, CXCL 
10 and IL-8 following exposure of the cells to colonic media after dosing 
with Symprove for 24 h. For all donors, treatment with probiotic 
increased NF-κB activity and concomitant secretion of the anti- 
inflammatory cytokines compared with the untreated controls and IL- 
8 levels decreased. CXCL10 levels were increased while TNFα levels 
were highly dependent on the donor. 
For all donors, treatment with Symprove increased NF-κB activity 
and concomitant secretion of the anti-inflammatory cytokines compared 
with the untreated controls. While IL-10 is considered to be a 
prototypical anti-inflammatory cytokine, IL-6 can exert both pro- and 
anti-inflammatory effects (Scheller et al., 2011). Indeed, IL-6 was shown 
to inhibit the secretion of pro-inflammatory cytokines, such as IL-1β. 
Furthermore, in the gut, IL-6 demonstrated positive effects on epithelial 
regeneration and wound healing (Dann et al., 2008). Therefore the 
increased secretion of IL-6 upon treatment in this ‘leaky gut’ model 
could be seen as beneficial in terms of protection of the epithelial bar-
rier. Likewise, NF-κB activation has been linked to both pro- and anti- 
inflammatory functions (Pires et al., 2018), including expression of IL- 
10 (Lyer and Cheng, 2012). Hence, NF-κB activation under inflamma-
tory conditions leads additionally to the upregulation of anti- 
inflammatory cytokines, needed to resolve the inflammation and pre-
vention of tissue disruption. 
Although NF-κB inhibition has been proposed as a therapeutic 
intervention in PD to prevent microglia activation and neuro-
degeneration (Flood et al., 2011), butyrate-induced NF-κB activation in 
the inflamed gut might restore the balance to a rather anti-inflammatory 
state by differential modulation of cytokines due to its HDAC inhibitory 
potential (Vinolo et al., 2011). 
Secretion of the pro-inflammatory cytokines and chemokines TNFα, 
CXCL 10 and IL-8 were modulated following exposure of the cells to 
colonic media with Symprove for 24 h. For all donors, IL-8 levels 
decreased upon probiotic dosing although CXCL10 levels were 
increased. TNFα levels were highly dependent on the donor. For PD 
microbiomes, upon probiotic dosing TNFα secretion was raised in donor 
1, while the levels decreased in donors 2 and 3, but these changes were 
not statistically significant. Thus, treatment with Symprove demon-
strated some positive effects on inflammation by increasing the secretion 
of anti-inflammatory cytokines, while decreasing some, but not all, pro- 
inflammatory cytokines and chemokines tested in the co-culture model 
used. As above, a principal component analysis plot (Fig. S2) is given in 
SI for both healthy and PD donors, showing the change in TEER and 
inflammatory markers following dosing with Symprove. 
Fig. 6 shows images of the scratch wound as created and after 24 h 
exposure to complete medium (CM), sodium butyrate and healthy donor 
microbiotas (with and without probiotic). Fig. 7 shows similar images 
for PD donors (note that the data for donor 3 were excluded due to 
toxicity of the sample to the T84 cells). Calculated percentages of the 
wound closures are given in Table 10. In all cases, dosing with probiotic 
significantly (p < 0.001) increased wound healing compared with the 
control. 
After 24 h, the CM sample wound had reduced to 75% of its initial 
area while the sodium butyrate wound reduced significantly (p <
0.0001) more, to 45% of its initial area. In all cases, dosing with 
Fig. 3. Effect of colonic batch samples from patients with PD, compared with 
colonic batch samples from healthy controls, on the NF-κB activity of THP1- 
Blue™ cells. (*) represents statistically significant differences between the 
control and probiotic-dosed, p < 0.1; (**) p < 0.01. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
Fig. 4. Effect of colonic batch samples from patients with PD, compared with colonic batch samples from healthy controls, on secretion of anti-inflammatory cy-
tokines IL-6 (left) and IL-10 (right). (*) represents statistically significant differences between the control and probiotic-dosed samples, p < 0.1; (**) p < 0.01; (***) p 
< 0.001; (****) p < 0.0001. 
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probiotic significantly (p < 0.001) increased wound healing compared 
with the control. Again, the results suggest that it is not the presence of 
the probiotic species that positively influences wound healing; rather, 
butyrate is the key factor that encourages wound closure and the posi-
tive results from dosing with probiotic arise from increased SCFA con-
centrations from stimulation of the commensal gut bacteria. 
Fig. 5. Effect of colonic batch samples from patients with PD, compared with 
colonic batch samples from healthy controls, on secretion of inflammatory 
cytokines TNFα (top), CXCL 10 (middle) and IL-8 (bottom). 
Fig. 6. Images of the wound area of T84 cells at the start of treatment (0 h) and 
after incubation (24 h) for healthy control donors. Treated with (A) complete 
medium (B) sodium butyrate, (C) Donor 1 control, (D) Donor 1 dosed with 
probiotic, (E) Donor 2 control, (F) Donor 2 dosed with probiotic, (G) Donor 3 
control and (H) Donor 3 dosed with probiotic. 
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4. Summary 
This work suggests that probiotic supplementation might improve 
gut health in PD patients. It is not just the simple presence of the pro-
biotic bacteria that causes these positive effects, but a cascade of events 
(proliferation of the probiotic bacteria generating lactate, lactate stim-
ulating propionate- and butyrate-producing commensal species) leading 
to raised levels of butyrate. If development and/or progression of PD is 
influenced by gut microbiota dysbiosis then supplementation of the diet 
with a properly formulated probiotic may be a useful adjunct to standard 
treatment in clinic. Because of the small number of donors, results 
should be interpreted with caution and need replication, but combined 
with human and animal data they provide a compelling indication that 
probiotics may be a potential and cost-effective intervention in man-
aging patients with Parkinson's Disease. 
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